Helicobacter pylori Infections - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Helicobacter pylori Infections - Pipeline Review, H2 2016

Helicobacter pylori Infections - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Helicobacter pylori Infections - Pipeline Review, H2 2016
Published Jul 13, 2016
75 pages — Published Jul 13, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Helicobacter pylori Infections - Pipeline Review, H2 2016, provides an overview of the Helicobacter pylori Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Helicobacter pylori Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Helicobacter pylori Infections and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Helicobacter pylori Infections
- The report reviews pipeline therapeutics for Helicobacter pylori Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Helicobacter pylori Infections therapeutics and enlists all their major and minor projects
- The report assesses Helicobacter pylori Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Helicobacter pylori Infections

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Helicobacter pylori Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics

  
Source:
Document ID
GMDHC8283IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Helicobacter pylori Infections Overview71
Therapeutics Development82
  Pipeline Products for Helicobacter pylori Infections Overview81
  Pipeline Products for Helicobacter pylori Infections Comparative Analysis91
Helicobacter pylori Infections Therapeutics under Development by Companies101
Helicobacter pylori Infections Therapeutics under Investigation by Universities/Institutes111
Helicobacter pylori Infections Pipeline Products Glance123
  Late Stage Products121
  Clinical Stage Products131
  Early Stage Products141
Helicobacter pylori Infections Products under Development by Companies151
Helicobacter pylori Infections Products under Investigation by Universities/Institutes161
Helicobacter pylori Infections Companies Involved in Therapeutics Development1710
  Daewoong Pharmaceutical Co., Ltd.171
  Debiopharm International SA181
  EpiVax, Inc.191
  Frost Biologic, Inc.201
  ImevaX GmbH211
  ImmunoBiology Limited221
  Recce Pty Ltd231
  RedHill Biopharma Ltd.241
  Sequella, Inc.251
  Sigmoid Pharma Limited261
Helicobacter pylori Infections Therapeutics Assessment279
  Assessment by Monotherapy Products271
  Assessment by Combination Products281
  Assessment by Target292
  Assessment by Mechanism of Action312
  Assessment by Route of Administration331
  Assessment by Molecule Type342
Drug Profiles3621
  (amoxicillin sodium + omeprazole sodium + rifabutin) Drug Profile364
  Debio-1453 Drug Profile401
  DWJ-1325 Drug Profile411
  FROST-900 Drug Profile421
  Helicobacter pylori [strain Hel-305] (multivalent) vaccine Drug Profile431
  Helicobacter pylori vaccine Drug Profile441
  Helicobacter pylori vaccine Drug Profile451
  Helicobacter pylori vaccine Drug Profile461
  Helicobacter pylori vaccine Drug Profile471
  HPi-1 Drug Profile481
  IMX-101 Drug Profile491
  RECCE-327 Drug Profile501
  Small Molecules for Helicobacter Pylori Infections Drug Profile511
  Small Molecules to Inhibit DNA Synthesis for Infectious Diseases Drug Profile521
  SQ-109 Drug Profile534
Helicobacter pylori Infections Dormant Projects571
Helicobacter pylori Infections Product Development Milestones5816
  Featured News &Press Releases581
    Apr 18, 2016: RedHill Announces Positive FDA Meeting on RHB-105 Path to Approval and Planned Confirmatory Phase III Study for H. pylori Infection581
    Mar 08, 2016: RedHill Biopharma Reports Successful Final Results of Phase III Study with RHB-105 for H. pylori Infection591
    Mar 01, 2016: RedHill Biopharma Provides Update on RHB-105601
    Sep 08, 2015: RedHill Announces Standard-of-Care Eradication Data from the RHB-105 Phase III Study Further Supporting the Study s Positive Results611
    Aug 26, 2015: Recipharm Signs Agreement with RedHill Biopharma for Manufacturing of RHB-105 for treatment of H. pylori infection621
    Jun 15, 2015: RedHill Biopharma Successfully Meets Primary Endpoint in Phase III Study of RHB-105 for H. pylori Infection631
    Jun 15, 2015: RedHill Biopharma to Host Conference Call to Review Positive Phase III Top-Line Results with RHB-105 for H. pylori Infection641
    Jun 08, 2015: RedHill Biopharma Completes Treatment of Last Patient with RHB-105 in Phase III Study641
    Jun 03, 2015: RedHill Biopharma Provides Update on Development Pipeline and Expected Timing for RHB-105 Phase III Top-Line Results652
    May 18, 2015: RedHill Biopharma s Investor Webcast Forum Provides Update on the RHB-105 Phase III Program and Potential H. Pylori Eradication Market671
    May 07, 2015: RedHill Biopharma to Host Investor Webcast Forum Following Completion of RHB-105 Dosing in Phase III Study681
    Apr 27, 2015: RedHill Biopharma Announces Completion of Patient Enrollment in a Phase III Study of RHB-105 for H. pylori Infection691
    Apr 16, 2015: RedHill Biopharma Receives Notice of Allowance for Additional U.S. Patent for RHB-105 H. pylori Bacterial Infection Treatment701
    Nov 10, 2014: FDA Grants QIDP Fast-Track Designation To RedHill Biopharma's Phase 3 H. Pylori Drug RHB-105711
    Aug 27, 2014: RedHill Biopharma Provides Update on Expansion of Ongoing RHB-105 Phase III Study, Targeting Broadened H. pylori Indication Authorized by FDA722
Appendix742
  Methodology741
  Coverage741
  Secondary Research741
  Primary Research741
  Expert Panel Validation741
  Contact Us741
  Disclaimer751

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Helicobacter pylori Infections - Pipeline Review, H2 2016" Jul 13, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Helicobacter-pylori-Infections-Pipeline-Review-H2-2016-2088-16178>
  
APA:
Global Markets Direct - Market Research. (2016). Helicobacter pylori Infections - Pipeline Review, H2 2016 Jul 13, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Helicobacter-pylori-Infections-Pipeline-Review-H2-2016-2088-16178>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.